Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19
Do not use the medication until you have consulted your pharmacist or GP surgery
The biological evaluation relies primarily on the MTT assay and involves a relatively small number of cancer cell lines, which restricts the robustness of the pharmacological interpretation
The approved NHS pathways are: Wegovy (semaglutide) licensed for weight management via NICE TA875 (BMI 35+ with one condition, via tier 3 services) and NICE cardiovascular guidance April 2026 (BMI 27+ with established CVD, via GP) Mounjaro (tirzepatide) licensed for weight management via NICE TA1026 (BMI 35+ with four conditions from June 2026, via tier 3 or QOF GP pathway) Ozempic (semaglutide) NOT approved for NHS weight management
Han MN, Lu JM, Zhang GY, Yu J, Zhao RH
US$ 21.40
US$ 25.51
US$ 29.96
US$ 29.75
